Metalytics LLC Company Profile

Background

Overview

Metalytics LLC is a biotechnology company specializing in metabolic flux analysis (MFA) to optimize cell-based manufacturing processes for biochemicals, pharmaceuticals, and food products. Founded in 2016 and headquartered in Morrisville, North Carolina, Metalytics offers innovative solutions that enhance productivity, product quality, and process robustness in biomanufacturing.

Mission and Vision

Metalytics is dedicated to advancing biopharmaceutical and biomanufacturing process development through predictive digital twins. By leveraging artificial intelligence and biochemical networks, the company aims to reduce experimental efforts, lower production costs, and accelerate time-to-market for its clients.

Industry Significance

Operating within the biotechnology sector, Metalytics plays a crucial role in optimizing cell culture processes, which are fundamental to the production of various bioproducts. Its technologies are utilized by leading biopharmaceutical companies worldwide for cell line development and media design, contributing to advancements in drug development and biomanufacturing efficiency.

Key Strategic Focus

Core Objectives

Process Optimization: Enhancing cell culture processes to improve yield and quality.

Cost Reduction: Minimizing experimental efforts and production costs.

Accelerated Development: Shortening time-to-market for biopharmaceutical products.

Areas of Specialization

Cell Line Development: Engineering improved cell lines for biomanufacturing.

Media Design: Optimizing cell culture media components.

Metabolic Analysis: Assessing cellular metabolic rates in vitro and in vivo.

Key Technologies Utilized

Artificial Intelligence: Employing AI to analyze process data.

Biochemical Networks: Utilizing biochemical networks for predictive modeling.

Digital Twins: Creating predictive digital twins of cell culture processes.

Primary Markets Targeted

Biopharmaceuticals: Drug development and manufacturing.

Specialty Chemicals: Production of specialized chemical products.

Biofuels and Bioproducts: Renewable energy and bioproduct manufacturing.

Synthetic Biology: Engineering biological systems for various applications.

Agricultural Biotechnology: Enhancing agricultural products through biotechnology.

Cell-Based Protein and Food Production: Developing sustainable food sources.

Financials and Funding

Funding History

Metalytics has secured funding through grants from the National Science Foundation (NSF). Specific details regarding the total funds raised and the amounts of individual grants are not publicly disclosed.

Utilization of Capital

The capital raised is intended to support the development and commercialization of Metalytics' technologies, including the CoreMFA Big Data platform, which aids in optimizing cell line selection and cell culture media components.

Pipeline Development

Key Pipeline Candidates

Metalytics focuses on developing technologies that enhance cell culture processes, leading to superior productivity, product quality, and process robustness. Specific pipeline candidates and their stages are not publicly detailed.

Target Conditions

The company's technologies are designed to optimize processes in various industries, including biopharmaceuticals, specialty chemicals, biofuels, and agricultural biotechnology.

Anticipated Milestones

While specific timelines for anticipated milestones are not publicly disclosed, Metalytics continues to advance its technologies to meet the evolving needs of its target markets.

Technological Platform and Innovation

Proprietary Technologies

CoreMFA Big Data Platform: A platform that enables rapid and rational engineering of improved cells and optimization of cell culture media components.

Significant Scientific Methods

Metabolic Flux Analysis (MFA): A technique used to determine biochemical reaction rates inside living cells, providing insights into cellular metabolic pathways.

AI-Driven Capabilities

Predictive Digital Twins: Utilizing artificial intelligence to create digital representations of cell culture processes, allowing for predictive modeling and optimization.

Leadership Team

Executive Profiles

Eric Cumming, MBA – Chief Executive Officer

With over 25 years of experience in technology, health, and biotechnology, Eric has held roles in product development, technology architecture, and investment fundraising. He earned his MBA from the University of Michigan and his BSc from Oakland University.

Stephanie Chandler, MBA – Executive Vice President of Operations

Stephanie brings over 20 years of experience in operations management and strategic execution across life sciences and technology sectors. She holds an MBA and is known for building scalable, high-performance teams that support the company’s growth in biomanufacturing, drug development, and metabolic analysis.

Sam Yenne, PhD, MBA – Chief Commercial Officer

Sam has over 25 years of corporate leadership along with product discovery and development expertise in the life sciences and related industries. He earned his MBA from Duke University, his PhD from Virginia Tech, and his BS and MS degrees from the University of Idaho.

Daniel Benjamin, PhD – Chief Scientific Officer

Daniel received his Ph.D. in metabolic biochemistry from UC Berkeley and was a post-doctoral fellow at Stanford University. His research has focused on metabolic pathways critical for promoting aggressive features of cancer and developing small molecule inhibitors targeting these pathways.

Thomas DiProspero, PhD – Director of Product Development

Thomas received his Ph.D. in Chemistry from the University of North Carolina at Chapel Hill. He engineered an in vitro liver model to improve the predictability of preclinical drug development and collaborated with university scientists to develop commercial products from academic IP.

Competitor Profile

Market Insights and Dynamics

The biotechnology sector, particularly in metabolic analysis and cell-based manufacturing optimization, is experiencing growth driven by the increasing demand for efficient and cost-effective production processes. Companies like Metalytics are at the forefront of this trend, offering innovative solutions to meet industry needs.

Competitor Analysis

Culture Biosciences: Focuses on bioprocess development and optimization.

Multispan: Provides cell culture media and reagents.

Enrich Biosystems: Specializes in cell culture media and supplements.

Strategic Collaborations and Partnerships

Metalytics collaborates with leading biopharmaceutical companies worldwide, leveraging its technologies for cell line development and media design.

Operational Insights

Metalytics differentiates itself through its unique approach to metabolic analysis, utilizing artificial intelligence and biochemical networks to create predictive digital twins of cell culture processes. This innovation substantially reduces experimental effort, costs of goods, and time to market.

Strategic Opportunities and Future Directions

Metalytics is well-positioned to expand its market presence by continuing to innovate in metabolic analysis technologies and by forming strategic partnerships to enhance its offerings in biopharmaceuticals, specialty chemicals, and other target markets.